A MnO₂-based tumor-seeking nanoplatform for enhanced chemoimmunotherapy against 4T1 breast cancer.

ABSTRACT: A significant obstacle in oncological therapy lies in surmounting the immunosuppressive microenvironment while enhancing the anti-tumor efficacy of chemotherapeutic agents. STING agonists such as Mn²⁺ have demonstrated substantial promise in this regard. Squamocin (Squ), a naturally derived compound, exhibits potent anti-tumor activity with minimal drug resistance; however, its application is hampered by poor water solubility (approximately 7.5 μg/mL) and off-target toxicity. In this study, a chemo-immunotherapy approach utilizing MnO₂ nanoparticles combined with squamocin (Squ) has been formulated, with its therapeutic effectiveness further augmented through surface modification with the tumor-targeting IR820 molecule. The intravenously injectable MnO₂ nan

SUBMITTER: Gong T 

PROVIDER: S-EPMC12272469 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature